Patents Represented by Attorney Thomas Dodd
-
Patent number: 7943653Abstract: This invention is directed to a cannabinoid modulator compound of formula (I): or a form thereof, and methods for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.Type: GrantFiled: August 11, 2008Date of Patent: May 17, 2011Assignee: Janssen Pharmaceutica N.V.Inventors: Mingde Xia, Meng Pan, Michael P. Wachter
-
Patent number: 7902225Abstract: The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemically isomeric forms thereof the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases. In particular, compounds are claimed in which, independently from each other, R1 is halo; p=1; R2 is optionally substituted alkyloxy, alkyl, Ar, Het, or a radical of formula R3 is optionally substituted Ar or Het; q=1, R4 and R5 each independently are alkyl; R6 is hydrogen or a radical of formula r is equal to 0 or 1 and R7 is hydrogen or Ar.Type: GrantFiled: January 21, 2005Date of Patent: March 8, 2011Assignee: Janssen Pharmaceutica NVInventors: Jérôme Emile Georges Guillemont, Elisabeth Therese Jeanne Pasquier, David Francis Alain Lancois
-
Patent number: 7902227Abstract: The present invention relates to C-7 isoxazolyl quinoline/naphthyridine derivatives useful as antimicrobial compounds, pharmaceutical compositions comprising said derivatives and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.Type: GrantFiled: July 28, 2008Date of Patent: March 8, 2011Assignee: Janssen Pharmaceutica NV.Inventors: Mark J. Macielag, Michele A. Weidner-Wells, Shu-Chen Lin
-
Patent number: 7642270Abstract: The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: W, A, Y, Z, R101 and R200 are described in the specification.Type: GrantFiled: September 12, 2006Date of Patent: January 5, 2010Assignee: Janssen Pharmaceutica N.V.Inventors: Mark R. Player, Hui Huang, Daniel A. Hutta, Renee L. DesJarlais
-
Patent number: 7524964Abstract: The invention relates to a CB modulator compound of Formula (I) or a pharmaceutically acceptable form thereof and a method for use in treating, ameliorating or preventing a CB receptor mediated syndrome, disorder or disease.Type: GrantFiled: December 7, 2007Date of Patent: April 28, 2009Assignee: Janssen Pharmaceutica NVInventors: Fina Liotta, Huajun Lu, Mingde Xia, Michael P. Wachter
-
Patent number: 7476672Abstract: This invention is directed to acetylenic compounds as inhibitors of a nicotinamide adenine dinucleotide oxidase hydride donor useful in treating or ameliorating a reactive oxygen species mediated inflammatory disorder.Type: GrantFiled: January 10, 2006Date of Patent: January 13, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: Scott Beers, Elizabeth A. Malloy, Michael P. Wachter
-
Patent number: 7452997Abstract: This invention is directed to a tetrahydro-indazole cannabinoid modulator compound of formula I: and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.Type: GrantFiled: March 23, 2005Date of Patent: November 18, 2008Assignee: Janssen Pharmaceutica, N.V.Inventors: Bharat Lagu, Fina Liotta, Meng Pan, Michael P. Wachter, Mingde Xia Xia
-
Patent number: 7414048Abstract: The present invention is concerned with the compounds of formula wherein m, n and p are each independently 0 or 1 and q is 0, 1, 2, 3, 4 or 5; -A1=A2-A3=A4- is a pyridinylidene, pyridazinylidene, pyrimidinylidene, pyrazinylidene or phenylidene; B represents an amide, ketone or oxadiazole; D represents Ar or Het; Q represents a covalent direct bond or a ketone, —N—, —O—, —CR5R6—, amide, ethenyl, imine, sulfonyl, sulfinyl, 3-oxobutenyl, pyrazole, isoxazole or thiazole; L represents Ar or Het; R1 represents hydrogen, halo, hydroxy, C(2-6)alkenyl, C(2-6)alkynyl, C(3-6)cycloalkyl, C(3-6)cycloalkenyl, cyano, guanidine, nitro, NR17R18, an optionally substituted C(1-6)alkyl or C(1-6)alkyloxy; R2 and R3 each independently represent hydrogen, halo, C(1-6)alkyloxy or an optionally substituted C(1-6)alkyl; R5 and R6 each independently represent hydrogen, hydroxy, halo, an optionally substituted C(1-6)alkyl, C(2-6)alkenyl, C(2-6)alkynyl, C(3-6)cycloalkyl, C(3-6)cycloalkenyl, C(1-6)alkyloxy, cyano, (C?O)R25, (C—O)OR16,Type: GrantFiled: March 31, 2003Date of Patent: August 19, 2008Assignee: Janssen Pharmaceutica, N.V.Inventors: Eddy Jean Edgard Freyne, José Ignacio Andrés-Gil, Frederik Dirk Deroose, Davy Petrus Franciscus Maria Petit, Maria Encarnacion Matesanz-Ballesteros, Rosa Maria Alvarez Escobar
-
Patent number: 7338952Abstract: This invention is directed to acetylenic compounds as inhibitors of a nicotinamide adenine dinucleotide oxidase hydride donor useful in treating or ameliorating a reactive oxygen species mediated inflammatory disorder.Type: GrantFiled: January 10, 2006Date of Patent: March 4, 2008Assignee: Janssen Pharmaceutica N.V.Inventors: Scott Beers, Elizabeth A. Malloy, Michael P. Wachter
-
Patent number: 7338949Abstract: The present invention relates to novel substituted quinoline derivatives according to the general formula (Ia) or the general formula (Ib) salts, quaternary amines, stereochemically isomeric forms, tautomeric forms and N-oxide forms thereof, wherein R1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2, 3 or 4; R2 is hydrogen, hydroxy, thio, alkyloxy, alkyloxyalkyloxy, alkylthio, mono or di(alkyl)amino or a radical of formula R3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; R4 is hydrogen, alkyl or benzyl; R5 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R5 radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl; r is 1, 2, 3, 4 or 5; R6 is hydrogen, alkyl, Ar or Het; R7 is hydrogen or alkyl; R8 is oxo; or R7 and R8 taken together form the radical —CH?CH—N?; Z isType: GrantFiled: January 21, 2005Date of Patent: March 4, 2008Assignee: Janssen Pharmaceutica N.V.Inventors: Jérôme Emile Georges Guillemont, Elisabeth Therese Jeanne Pasquier
-
Patent number: 7262197Abstract: This invention is directed to heterocyclyl-substituted anilino phospholipase C inhibitor compounds useful in treating or ameliorating an inflammatory disorders and/or restenosis of the general formula (I): and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions affected by phospholipase modulation.Type: GrantFiled: March 31, 2004Date of Patent: August 28, 2007Assignee: Janssen Pharmaceutica, N.VInventors: Bharat Lagu, Kenneth Rupert, Michael Wachter
-
Patent number: 7138403Abstract: This invention concerns the use of a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; C1-6alkyl; C1-6alkyl substituted with hydroxy, carboxyl, cyano, amino, mono- or di(C1-6alkyl)amino, aminocarbonyl, mono- or di(C1-6alkyl)aminocarbonyl, C1-6alkyloxycarbonyl or C1-6alkyloxy; polyhaloC1-4alkyl; C1-4alkyloxy; cyano; amino; aminocarbonyl; mono- or di(C1-6alkyl)aminocarbonyl; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; H2N—S(?O)2—; mono- or di(C1-6alkyl)amino-S(?O)2; —C(?N—Rx)NRyRz; Q is an optionally substituted carbocycle or an optionally substituted heterocycle; L is substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of diseases mediated through TNF-? and/or IType: GrantFiled: August 9, 2002Date of Patent: November 21, 2006Assignee: Janssen Pharmaceutica N.V.Inventors: Christopher John Love, Jean Pierre Frans Van Wauwe, Marc J. De Brabander, Roger Clive Moses, Mykhalyo Goncharenko, Ludwig Paul Cooymans, Nele Vandermaesen, Gaston Stanislas Marcella Diels, Anthony William Sibley, Caterina Noula
-
Patent number: 7087622Abstract: In accordance with the present invention, compounds that inhibit Type III protein section have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of Type III protein section and/or in the treatment and prevention of bacterial infections, particularly Gram-negative bacterial infections, are provided. In another aspect of the invention, methods are provided for the inhibition of Type III protein secretion and/or the treatment and prevention of bacterial infections, particularly Gram-negative bacterial infections using the compounds of the invention.Type: GrantFiled: May 6, 2005Date of Patent: August 8, 2006Assignee: Janssen Pharmaceutica N.V.Inventor: Xiaobing Li
-
Patent number: 7067671Abstract: The present invention relates to a process for preparing tetrasubstituted imidazole derivatives of the general formula (I) wherein R1, R2, R3 and R4 are as defined in the specification below. The present invention further relates to a process for preparing the compound of formula (II) and novel crystalline structures of the compound of formula (II).Type: GrantFiled: February 22, 2002Date of Patent: June 27, 2006Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Hua Zhong, Silke Dubberke, Stefan Müller, Armin Rossler, Thomas W. Schultz, Daniel J. Korey, Thomas Otten, Donald G. Walker, Ahmed Abdel-Magid
-
Patent number: 7022703Abstract: This invention is directed to acetylenic compounds as inhibitors of a nicotinamide adenine dinucleotide oxidase hydride donor useful in treating or ameliorating a reactive oxygen species mediated inflammatory disorder.Type: GrantFiled: July 24, 2003Date of Patent: April 4, 2006Assignee: Janssen Pharmaceutica, N.V.Inventors: Scott Beers, Elizabeth A. Malloy, Michael P. Wachter
-
Patent number: 6951863Abstract: Pyridoarylphenyl oxazolidinone compounds of the formula: in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.Type: GrantFiled: February 6, 2002Date of Patent: October 4, 2005Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Steven D. Paget, Michele A. Weidner-Wells, Harvey M. Werblood